Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
about
The Promise and Challenge of Therapeutic MicroRNA Silencing in Diabetes and Metabolic DiseasesBile acid signaling in metabolic disease and drug therapyEpigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field.Potential Role of Lipometabolism-Related MicroRNAs in Peripheral Blood Mononuclear Cells as Biomarkers for Coronary Artery Disease.Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cellsRecent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players.Potential epigenetic mechanism in non-alcoholic Fatty liver diseaseInhibition of miR-29 has a significant lipid-lowering benefit through suppression of lipogenic programs in liver.MicroRNAs and Noncoding RNAs in Hepatic Lipid and Lipoprotein Metabolism: Potential Therapeutic Targets of Metabolic Disorders.Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different gradesLiver MicroRNA-291b-3p Promotes Hepatic Lipogenesis through Negative Regulation of Adenosine 5'-Monophosphate (AMP)-activated Protein Kinase α1.Systematic analysis of the regulatory functions of microRNAs in chicken hepatic lipid metabolism.The persistence of low-grade inflammatory monocytes contributes to aggravated atherosclerosis.MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway.The microRNA regulatory network: a far-reaching approach to the regulate the Wnt signaling pathway in number of diseases.Role of MicroRNAs in NAFLD/NASH.miRNA and cholesterol homeostasis.The multifactorial nature of microRNAs in vascular remodelling.Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?HDL and microRNA therapeutics in cardiovascular disease.MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease.miRNAs in non-alcoholic fatty liver disease.The role of microRNAs in hepatocyte metabolism and hepatitis B virus replication.Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.MicroRNA-206 Prevents the Pathogenesis of Hepatocellular Carcinoma Via Modulating Expression of cMet and Cdk6.MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesisIdentification of microRNAs controlling hepatic mRNA levels for metabolic genes during the metabolic transition from embryonic to posthatch development in the chicken.MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1.Systems genetics identifies a co-regulated module of liver microRNAs associated with plasma LDL cholesterol in murine diet-induced dyslipidemia.Mir-24 regulates hepatocyte apoptosis via BIM during acute liver failure.Ultraconserved element uc.372 drives hepatic lipid accumulation by suppressing miR-195/miR4668 maturation.Integrative analysis of microRNAs and mRNAs revealed regulation of composition and metabolism in Nelore cattle.MicroRNA and Adipogenesis.MicroRNAs as Potential Regulators of Glutathione Peroxidases Expression and Their Role in Obesity and Related Pathologies.Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver diseaseDifferences in circulating microRNA signature in Prader-Willi syndrome and non-syndromic obesity
P2860
Q26750496-A79EEF9C-24CE-4DA6-B97A-AB6394C058C5Q28244875-08D81143-0798-4779-933D-944F7BB51589Q30400120-799E8455-EFFA-4CB3-896E-64D1C7AA7A87Q33567332-4AF610D6-8987-491A-92ED-C80E9473BCC7Q33807881-4F4AB8A9-E5B1-4D7D-9E52-1385C51F50DDQ34821020-4821A705-4A27-4220-A50F-7294B6C685B1Q35380845-7E821B00-CB09-434B-BDBD-45F7B54E3CD8Q35922081-999511BD-079A-430C-811A-A9069BB9EFE6Q36599274-A5AF2800-3137-4F40-9AAC-FCA4A2040E60Q36764809-9391DE1F-2A9D-46B1-8FC0-B5CF0E30E2FBQ36898227-755EBEF5-F988-4E56-B0C6-ACD957794B6EQ37184805-0B73B850-DAD8-4AF7-928F-7922C1C980F3Q37408646-2AE6EE01-8AA4-41BC-BA27-6E451B582858Q38297030-3273ADA6-1FF9-4A93-967E-D610968F11D3Q38622178-2C1911D3-7D82-4292-A1DA-52B780BC018DQ38697221-183F636E-8028-40C1-BF8E-110D6A9D3D8AQ38700512-441D9D29-8D74-4415-BA10-32BD02EE8197Q38749173-2FD5AD01-D24C-4B94-B9A8-3B10F968B7D7Q38813514-33531DAA-DCA5-4B12-9103-E68C7324A84FQ38824208-9032F584-2563-49F9-B7BE-B633F01E9A7DQ38954546-4C9BF9AA-EAE3-4A02-9FBA-63C1A2511877Q38966905-868D350A-2966-4511-8685-2532A4E3C010Q39072215-8B4A76E2-1649-4355-A674-CAE88D4D3B2FQ40061048-BB84DCB9-674F-40B7-9BAD-ECD627A59D20Q40132515-D83A7BA0-F57B-4BDC-8D8B-34C6BDB53E51Q41495543-1A3A9C40-F8B0-4A64-BB87-0019A9388627Q41611022-3313BADB-A2A4-40BE-9710-55384B922550Q44303902-1EFAE9A7-5190-4BBB-9DD3-78168C3D97EFQ46067590-09F664C9-9B66-4E03-A273-7EB423D0CAB3Q47125978-7F48F2F4-ACDF-49DB-86C1-7A60AEAE77DAQ49471259-AD3F2EC3-6B0F-4D29-83B7-B59FFBB07C32Q49589296-0FF909FD-FEC1-4457-BDE8-448982747516Q50957766-A776322F-E9F4-423F-8C2C-FA33D8E0EB15Q55128512-0CE0C7A1-9073-4871-8986-AC0FE0CAFB6CQ57067876-30195AB2-DAE2-4593-9D76-C2850101A007Q57818910-2A9DAC4C-A45D-4418-A644-535267BB77F1
P2860
Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.
@en
Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.
@nl
type
label
Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.
@en
Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.
@nl
prefLabel
Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.
@en
Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.
@nl
P2093
P2860
P356
P1433
P1476
Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.
@en
P2093
Clifford J Steer
Guisheng Song
Holger Willenbring
Raymond Ng
P2860
P304
P356
10.1002/HEP.27153
P407
P577
2014-05-19T00:00:00Z